SCHEMBL6989847

SCHEMBL6989847

O=C(NCC(O)CN1CCC(Cc2ccc(F)cc2)CC1)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.57
PRMT6 Q96LA8 1/20 0.57
GRIN2D O15399 1/20 0.53
GRIN3B O60391 1/20 0.53
ADRA1D P25100 1/20 0.53
ADRA1A P35348 1/20 0.53
ADRA1B P35368 1/20 0.53
GRIN1 Q05586 1/20 0.53
GRIN2A Q12879 1/20 0.53
GRIN2B Q13224 1/20 0.53
GRIN2C Q14957 1/20 0.53
GRIN3A Q8TCU5 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
DRD4 P21917 2/20 0.52
CCR3 P51677 5/20 0.52
ATM Q13315 1/20 0.52
ABCB1 P08183 2/20 0.51
PRMT5 O14744 1/20 0.51
WDR77 Q9BQA1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6990404 0.94 CARM1 (0.64) CARM1PRMT6GRIN2DGRIN3BADRA1D
SCHEMBL6997026 0.82 MEN1 (0.46) CARM1PRMT6GRIN2DGRIN3BADRA1D
SCHEMBL6214108 0.82 GRIN2D (0.51) GRIN2DGRIN3BADRA1DADRA1AADRA1B
SCHEMBL11889620 0.78 L3MBTL1 (0.49) PRMT5WDR77LMNAMAPTSMN1; SMN2
SCHEMBL10321630 0.78 OPRK1 (0.50) MEN1KMT2APRMT5WDR77LMNA
SCHEMBL18297341 0.78 L3MBTL1 (0.49) PRMT5WDR77LMNAMAPTSMN1; SMN2
SCHEMBL18975207 0.78 PRMT5 (0.49) PRMT5WDR77LMNAMAPTSMN1; SMN2
SCHEMBL10318194 0.78 OPRK1 (0.50) MEN1KMT2APRMT5WDR77LMNA
SCHEMBL6989963 0.76 GRIN2D (0.47) CARM1PRMT6GRIN2DGRIN3BADRA1D
SCHEMBL5352298 0.75 CCR3 (0.56) GRIN2BMEN1KMT2ACCR3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642256-B2 Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders WARNER-LAMBERT COMPANY LLC 2003-11-04 US disclosed
EP-1345935-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS Warner-Lambert Company LLC (US) 2003-09-24 EP disclosed
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists KORNBERG BRIAN EDWARD (US) 2003-01-23 US disclosed
WO-2002050070-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists GRIN1, OPRD1, OPRM1 CARM1 683/4885PRMT6 1074/4885GRIN2D 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.